Medical Editor: John P. Cunha, DO, FACOEP
Errin (norethindrone tablets) is a progestin-only oral contraceptive indicated for the prevention of pregnancy. Common side effects of Errin include:
- menstrual irregularity
- frequent and irregular bleeding
- long duration of bleeding episodes
- lack of menstrual period
- breast tenderness or pain
- unwanted hair growth
- weight gain
- abdominal pain
- pain in extremities
- vaginal discharge
- suppressed lactation
- withdrawal bleeding when product is stopped
- hair loss
- rash, and
To achieve maximum contraceptive effectiveness, Errin tablets must be taken exactly as directed. The dose of Errin is one tablet taken every day, at the same time. Administration is continuous, with no interruption between pill packs. Errin may interact with phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and bosentan. Tell your doctor all medications and supplements you use. Errin is not recommended for use during pregnancy. It is recommended to rule out suspected pregnancy before initiating any hormonal contraceptive use such as with Errin. Small amounts of progestins such as Errin pass into breast milk. Consult your doctor before breastfeeding.
Our Errin (norethindrone tablets) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Adverse reactions reported with the use of POPs include:
- Menstrual irregularity is the most frequently reported side effect.
- Frequent and irregular bleeding are common, while long duration of bleeding episodes and amenorrhea are less likely.
- Headache, breast tenderness, nausea, and dizziness are increased among progestin-only oral contraceptive users in some studies.
- Androgenic side effects such as acne, hirsutism, and weight gain occur rarely.
The following adverse reactions were also reported in clinical trials or during post-marketing experience: Gastrointestinal Disorders: vomiting, abdominal pain; General Disorders and Administration Site Conditions: fatigue, edema; Psychiatric Disorders: depression, nervousness; Musculoskeletal and Connective Tissue Disorders: pain in extremity; Reproductive System and Breast Disorders: genital discharge; breast pain, menstruation delayed, suppressed lactation, vaginal hemorrhage, menorrhagia, withdrawal bleed when product is stopped; Immune System Disorders: anaphylactic/anaphylactoid reaction, hypersensitivity; Hepatobiliary Disorders: hepatitis, jaundice cholestatic; Skin and Subcutaneous Tissue Disorders: alopecia, rash, rash pruritic.
Read the entire FDA prescribing information for Errin (Norethindrone Tablets USP)